About Aytu Bioscience (NASDAQ:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-0.123737329099088
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$3.22 million
Price / Sales5.22
Price / CashN/A
Book Value$4.84 per share
Price / Book0.71
Return on Equity-229.64%
Return on Assets-91.37%
Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions
What is Aytu Bioscience's stock symbol?
Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."
When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?
Aytu Bioscience's stock reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.
How were Aytu Bioscience's earnings last quarter?
Aytu Bioscience Inc (NASDAQ:AYTU) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($1.76) earnings per share for the quarter, beating the consensus estimate of ($7.60) by $5.84. The firm had revenue of $1.08 million for the quarter. Aytu Bioscience had a negative return on equity of 229.64% and a negative net margin of 481.06%. View Aytu Bioscience's Earnings History.
When will Aytu Bioscience make its next earnings announcement?
Where is Aytu Bioscience's stock going? Where will Aytu Bioscience's stock price be in 2018?
2 brokerages have issued 1-year price objectives for Aytu Bioscience's shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Aytu Bioscience's share price to reach $3.00 in the next twelve months. View Analyst Ratings for Aytu Bioscience.
Who are some of Aytu Bioscience's key competitors?
Some companies that are related to Aytu Bioscience include Prana Biotechnology (PRAN), Repros Therapeutics (RPRX), Bio-Path (BPTH), Fibrocell Science (FCSC), Burcon NutraScience (BUR), OncoGenex Pharmaceuticals (ACHV), OHR Pharmaceutical (OHRP), Yield10 Bioscience (YTEN), Synairgen (SNG), Precipio (PRPO), SenesTech (SNES), Jaguar Health (JAGX), Ampliphi Biosciences (APHB), RXi Pharmaceuticals (RXII), OpGen (OPGN), Ixico (IXI), ImmunoCellular Therapeutics (IMUC) and Rosetta Genomics (ROSG).
Who are Aytu Bioscience's key executives?
Aytu Bioscience's management team includes the folowing people:
- Joshua R. Disbrow, Chief Executive Officer, Director (Age 41)
- David A. Green CPA, Chief Financial Officer, Treasurer, Secretary (Age 55)
- Jarrett T. Disbrow, Chief Operating Officer
- Michael Macaluso, Director (Age 66)
- Gary V. Cantrell, Independent Director
- Carl C Dockery, Independent Director (Age 53)
- John Donofrio Jr., Independent Director
How do I buy Aytu Bioscience stock?
Shares of Aytu Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aytu Bioscience's stock price today?
One share of Aytu Bioscience stock can currently be purchased for approximately $3.43.
How big of a company is Aytu Bioscience?
Aytu Bioscience has a market capitalization of $13.76 million and generates $3.22 million in revenue each year. The company earns $-22,500,000.00 in net income (profit) each year or ($27.72) on an earnings per share basis. Aytu Bioscience employs 63 workers across the globe.
How can I contact Aytu Bioscience?
Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]
MarketBeat Community Rating for Aytu Bioscience (AYTU)MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aytu Bioscience (NASDAQ:AYTU) Earnings History and Estimates Chart
Aytu Bioscience (NASDAQ AYTU) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q1 2018||($7.60)||($1.76)||$1.08 million||View||N/A|
|5/11/2017||Q3 2017||($0.28)||($0.48)||$1.08 million||$0.89 million||View||N/A|
|2/9/2017||12/31/2016||($0.52)||($0.55)||$1.11 million||$0.79 million||View||N/A|
|11/7/2016||Q1 2017||($0.84)||($1.17)||$1.20 million||$0.70 million||View||N/A|
Aytu Bioscience (NASDAQ:AYTU) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Aytu Bioscience (NASDAQ:AYTU)
No dividend announcements for this company have been tracked by MarketBeat.com
Aytu Bioscience (NASDAQ AYTU) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.80%
Aytu Bioscience (NASDAQ AYTU) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/20/2016||Joshua R Disbrow||CEO||Buy||153,846||$0.65||$99,999.90||153,846|| |
Aytu Bioscience (NASDAQ AYTU) News Headlines
|Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?|
finance.yahoo.com - January 2 at 10:29 AM
|Aytu BioScience, Inc. to Present at the 10th Annual LD Micro Main Event|
finance.yahoo.com - November 29 at 10:48 AM
|Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.|
finance.yahoo.com - November 28 at 11:15 AM
|Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017|
finance.yahoo.com - November 28 at 11:15 AM
|BRIEF-Aytu Bioscience files for mixed shelf of upto $100 mln|
www.reuters.com - November 22 at 10:00 PM
|AYTU BIOSCIENCE, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - November 16 at 8:55 PM
|Q1 2017 Aytu BioScience Inc Earnings Release - Time Not Supplied|
biz.yahoo.com - November 7 at 1:40 PM
|AYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen|
biz.yahoo.com - November 2 at 10:18 PM
|Aytu BioScience Further Demonstrates Clinical Utility for MiOXSYS™ System as an Aid in the Diagnosis of Male Infertility|
www.prnewswire.com - November 1 at 9:11 PM
|Aytu BioScience to Present at Two Upcoming Investor Conferences|
www.prnewswire.com - September 14 at 3:43 PM
|Q4 2016 Aytu BioScience Inc Earnings Release - Time Not Supplied|
biz.yahoo.com - September 1 at 12:09 PM
|AYTU BIOSCIENCE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi|
biz.yahoo.com - September 1 at 12:09 PM
|Acerus Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q2 2016 Results - Earnings Call Transcript|
seekingalpha.com - August 9 at 4:48 PM
|AYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu|
biz.yahoo.com - August 2 at 8:29 AM
|Testosterone replacement treatment is opportunity for Colorado company|
www.bizjournals.com - July 8 at 8:52 PM
Aytu Bioscience (NASDAQ:AYTU) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Aytu Bioscience (NASDAQ AYTU) Stock Chart for Wednesday, January, 17, 2018